Browse IL11

Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF07400 Interleukin 11
Function

Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production (PubMed:2145578). Also promotes the proliferation of hepatocytes in response to liver damage. Binding to its receptor formed by IL6ST and either IL11RA1 or IL11RA2 activates a signaling cascade that promotes cell proliferation (PubMed:12919066). Signaling leads to the activation of intracellular protein kinases and the phosphorylation of STAT3.

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0018105 peptidyl-serine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018212 peptidyl-tyrosine modification
GO:0023061 signal release
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030183 B cell differentiation
GO:0030219 megakaryocyte differentiation
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0042113 B cell activation
GO:0043410 positive regulation of MAPK cascade
GO:0045444 fat cell differentiation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:1903531 negative regulation of secretion by cell
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005142 interleukin-11 receptor binding
GO:0008083 growth factor activity
GO:0070851 growth factor receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04630 Jak-STAT signaling pathway
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-6788467: IL-6-type cytokine receptor ligand interactions
R-HSA-168256: Immune System
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL11 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29662190Ovarian CarcinomaInhibit immunitySignificantly, clinic studies also confirm the activated IL-11-JAK2 pathway in platinum-resistant ovarian cancer patients, which highly correlates with poor prognosis.
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6460.28
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5420.582
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7170.384
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5380.462
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0830.421
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.160.929
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2910.71
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1160.926
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8470.544
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3190.473
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.460.0682
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL11
Nameinterleukin 11
Aliases IL-11; AGIF; adipogenesis inhibitory factor; oprelvekin; Interleukin-11
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.